We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · August 28, 2021

Body Mass Index, HbA1c, and Serum C-Reactive Protein Are Predictors of Secondary Failure in Infliximab Continuance for Psoriasis Patients

The Journal of Dermatology

 

Additional Info

The Journal of Dermatology
Body Mass Index, HbA1c and Serum C-Reactive Protein Are Predictors of Secondary Failure in Infliximab Continuance for Japanese Psoriasis Patients: A Hospital-Based Retrospective Case-Control Study
J Dermatol 2021 Aug 06;[EPub Ahead of Print], H Terui, M Asano, R Shimada-Omori, K Tsuchiyama, T Takahashi, M Nasu-Tamabuchi, A Hagiwara-Takita, Y Kusakari, T Ohtani, S Aiba, K Yamasaki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading